11^thWorld Congress on Precision and Personalized Medicine August 14-15, 2019 Auckland, New Zealand

Biography:

Reza rezaie khanghah: a chemist( freshman) at shahid rajaee teacher training university in tehran. 

20 year old from Iran . He learned English for six or seven years . he hasn't published another article except this and this one is his one experience.. he isn't  a member of  anywhere and wrote this manuscript alone with the help of God. He lives in Iran at Tehran and studied chemistry at shahid rajaee teacher training university.  Maybe he wants to  translate the book that the name is " Molecules that change the world " that the is for a specific kind of study at chemistry branches. He hopes to publish this manuscript  and find a home for his manuscript.

Abstract:

First of all I found lots of medicine for lots of diseases like phlegm and sore throat and headache and etc .I stated a Therapy for scrupulous and other kind of disease like this.Except disease and medical science and medicine and astronomy I have some other research into/on other fields of study.I found how stars moves at constellation and they have two general movements and in conclusion I say some of my studies here.you drink water at stand up stance it can cause you sweat a lot.My findings  support my hypothesis. My hypothesis is can we have natural medicine instead of chemicals one? Does any disease have medicine? Most scrutinized literature was collected from different sources including PubMed.This database has been curetted using published methods for all most all pharmaceuticals. Required information for regular method development/validation such as IUPAC name, structure, solubility, chromatographic conditions, instrumentation information like HPLC, LCMS detection parameters, sample preparations, recovery details, limit of detection and limit of quantification,Tmax,Cmax etc.,for routine application in BA/BE studies of pharmaceuticals was incorporated including official pharmacopeias information such as European Pharmacopeia, Japan Pharmacopeia and US Pharmacopeia. Database includes drug based bioanalytical methods covering most required fields and external database links of important drug portals such as drug bank, Rxlist, MEDLINE plus, KEGG Drug ID, KEGG Compound ID, Merck manual, PubChem compound ID, PubChem substance ID and USFDA.I use lots of studies and conducted my studies with lots of references that I said it at the end of my manuscript.

Biography:

Sergey Suchkov graduated from Astrakhan State Medical University and awarded with MD, then in 1985 maintained his PhD at the I.M. Sechenov Moscow Medical Academy and in 2001, maintained his Doctorship Degree at the Nat Inst of Immunology, Russia. From 1987 through 1989, he was a senior Researcher, Koltzov Inst of Developmental Biology. From 1989 through 1995, he was a Head of the Lab of Clinical Immunology, Helmholtz Eye Research Institute in Moscow. From 1995 through 2004, a Chair of the Dept for Clinical Immunology, Moscow Clinical Research Institute (MONIKI. Dr Suchkov has been trained at: NIH; Wills Eye Hospital, PA, USA; Univ of Florida in Gainesville; UCSF, S-F, CA, USA; Johns Hopkins University, Baltimore, MD, USA. He was an Exe Secretary-in-Chief of the Editorial Board, Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK. At present, Dr Sergey Suchkov is a Chair, Dept for Personalized and Translational Medicine, I.M.Sechenov First Moscow State Medical University. He is a member of the: New York Academy of Sciences, USA; American Chemical Society (ACS), USA; American Heart Association (AHA), USA; EPMA (European Association for Predictive, Preventive and Personalized Medicine), Brussels, EU; ARVO (American Association for Research in Vision and Ophthalmology); ISER (International Society for Eye Research); PMC (Personalized Medicine Coalition), Washington, USA.

Abstract:

Biography:

Dr. Schulz is an Assistant Professor of Laboratory Medicine at Yale School of Medicine. He received his MD and PhD in Microbiology, Immunology, and Cancer Biology from the University of Minnesota and completed his clinical training in Clinical Pathology and Transfusion Medicine at Yale. He is the Director of the CORE Center for Computational Health and the Medical Director of Data Science for Yale New Haven Health, where he manages the health system’s big data infrastructure, with a research focus on the development of real-time clinical predictive and prescriptive algorithms that can be used at the point-of-care.

Abstract:

Health care is in the midst of a digital transformation. The widespread adotpion of electronic health records, cost-effective genomic testing, and digital consumer health products now allow us to capture a detailed picture of an individual’s health, outside of traditional health care encounters. Using these data to develop digital therapeutics, analytic models, and real-time clinical decision support has gained significant interest, but harnessing these data to produce actionable information remains a challenge. The use of multiple ontologies, non-standard methods for real-world data collection and analysis, and the lack of secure and scalable computing infrastructure all pose barriers to the routine use of these data. To overcome these challenges, we have developed Baikal, a data analytics infrastructure that is able to acquire high-quality information from these digital health sources and integrate it with long-term outcomes to support biomedical research and the implementation of precision medicine initiatives. Using this infrastructure, which is built on open-source technologies, we have also developed Donatello, a framework that can support computational phenotyping, predictive and prescriptive model training, and the deployment of clinical analytic models within a production enviornment. We have used these platforms to assess real-world data quality, develop computed phenotypes in cardiology and oncology, and implement artifical intelligence methods to identify and predict outcomes in oncology care. The use of such platforms will allow us to scale these approaches and ensure high quality data and analytics to advance precision medicine.

Biography:

Lin Yu mainly work on antibody-cytotoxic drug conjugates during her Ph.D. study in Sichuan University. Antibody-based drugs (ADCs) have been developed and paid more attentions for tumor-targeting therapy. I had designed and generated four kinds of targeted ADCs and evaluate the anti-tumor effects in vitro and in vivo. And I have published three papers by the first author in journals. After graduation last years, she has been serving at the clinical laboratory of Mianyang Central Hospital and making efforts to establish the precision and personalized medicine plantform based on mass spectrometry  and next generation sequencing.

Abstract:

With the enormous increasing in knowledge about the molecular biology of cancers and the rapid developing in biotechnologies, a variety of biomarkers have been developed to detect cancer at an early stage and to monitor drug therapy. At present, the most common clinical used serum-tumor biomarkers are mainly including alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), neurone specific enolase (NSE), total prostate specific antigen (TPSA), human epididymis secretory protein 4 (HE4), carbohydrate antigen 125 (CA 125), carbohydrate antigen 153 (CA 153), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 72-4 (CA72-4) and serum ferrintin (SF). However, more and more studies have shown that serum markers are not only related to tumors, but also associated with other kinds of clinical diseases. In this study, we screened out the positive results for all mentioned above serum biomarkers and then statistically analyzed these positive results according to the patient's gender, age, disease type and the distribution of positive results. In last, we found that the elevated levels of serum markers were not only related with cancers, but also related with non-cancer diseases and offer a general view of relationship of those biomarkers with clinical diseases.